Dr Philip Molyneaux is a Reader in Interstitial lung disease and an Honorary Consultant at the Royal Brompton Hospital, where he is the director of the NIHR Clinical Research Facility.
Philip qualified from Guy's, King's and St Thomas' School of Medicine in 2004, where he completed an intercalated BSc. in Molecular Genetics. He undertook his SHO training at Guy’s and St Thomas’ and upon completion of the MRCP attained an NIHR Academic Clinical Fellow position in Respiratory medicine at Imperial College. He spent the next two years training at St Mary’s Hospital and working with Professors Cookson, Moffatt and Johnston studying the respiratory microbiome in COPD.
An Asmarley training fellowship allowed him to undertake a PhD examining the host response to the respiratory microbiome in Idiopathic Pulmonary Fibrosis as part of the Prospective Study of Fibrosis In the Lung Endpoints (PROFILE) study with Professor Maher.
Having completed his clinical training in Respiratory and Critical Care Medicine he returned to Imperial joining the Fibrosis Research Group as a Senior Clinical Lecturer. He was awarded the Action for Pulmonary Fibrosis Mike Bray Fellowship which enabled him to establish his research group studying the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis.
et al., 2022, Validation of proposed criteria for progressive pulmonary fibrosis., American Journal of Respiratory and Critical Care Medicine, ISSN:1073-449X
et al., 2022, Lung cancer screening provides an opportunity for early diagnosis and treatment of interstitial lung disease., Thorax
et al., 2022, Microbiome, metabolism, and immunoregulation of asthma: an American Thoracic Society and National Institute of Allergy and Infectious Diseases workshop report., American Journal of Respiratory Cell and Molecular Biology, Vol:67, ISSN:1044-1549, Pages:155-163
et al., 2022, Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1, Mucosal Immunology, ISSN:1933-0219
et al., 2022, Interstitial lung disease incidence and mortality in the United Kingdom and the European Union: an observational study, 2001-2017, Erj Open Research, Vol:8, ISSN:2312-0541, Pages:1-12